Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common hair loss drug help young cancer survivors regrow hair?

NCT ID NCT05778825

Symptom relief Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether oral minoxidil can improve persistent hair loss in children and young adults who survived cancer. Ten participants aged 6-18 who completed cancer treatment at least a year ago will receive either minoxidil or a placebo for 4 months. Researchers will measure hair density and check for side effects, aiming to see if this treatment is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
minoxidil (oral)
What this could lead to
If it works, this could offer a simple treatment option for hair loss in young cancer survivors, improving their quality of life.
What could go wrong
This is a very small pilot study (10 participants) and early-stage (Phase 2). It may not show significant benefit, and side effects or poor adherence could limit results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

10 people

The number who actually took part.

Started

Mar 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have been diagnosed with cancer before the age of 17. * They must have completed either systemic or radiation therapy (cytotoxic chemotherapy and external beam radiation therapy) for their cancer at least 1 year prior to study entry. * They must be between 6-18 years old at the time of enrollment. * They must have a clinical diagnosis of persistent or late alopecia for \>6 months and that is definitely, probably, or possibly related to prior chemotherapy and/or radiation. Exclusion Criteria: * Had a history of alopecia prior to systemic or radiation therapy for cancer, or has alopecia unrelated to cancer treatment. * Have scalp disorders that preclude the evaluation of alopecia, such as psoriasis * Has a known hypersensitivity to minoxidil * Concurrent use of other therapies for alopecia * Concurrent active anticancer therapies (cytotoxic, targeted, endocrine, immunologic) * History of chronic sclerotic cutaneous GvHD affecting the scalp * Active chronic cutaneous GvHD * History of orthostatic or symptomatic hypotension, syncope related to hypotension; systolic less than or equal than 100 (for adults) and 90 (for children) at screening. * Pregnancy. * Cardiovascular disease that in the opinion of the cardiologist makes the patient unsuitable for therapy * Blood pressure less than the 5th percentile or less than 90/50 mmHg for children 10 years or older

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia chemotherapy-induced alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia Survivors of childhood cancer

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.